PMP22 Antibody

Definition and Target Specificity

PMP22 antibodies are monoclonal or polyclonal antibodies that bind to specific epitopes of the PMP22 protein, a 22 kDa transmembrane glycoprotein encoded by the PMP22 gene on chromosome 17p12. PMP22 constitutes 2–5% of total myelin protein in Schwann cells and is essential for compact myelin formation . Key structural features targeted by these antibodies include:

• Four transmembrane domains

• Two extracellular loops (ECL1 and ECL2)

• Intracellular loop regions

Commercial antibodies like CF1 (Hycult Biotech) and OTI5D1 (OriGene) recognize human PMP22, with cross-reactivity in primates and rodents .

Applications in Research and Diagnostics

PMP22 antibodies are widely used in:

Autoimmune Neuropathies

• Anti-PMP22 antibodies are detected in 52% of Guillain-Barré syndrome (GBS) and 35% of chronic inflammatory demyelinating polyneuropathy (CIDP) patients, suggesting an autoimmune component .

• Experimental autoimmune neuritis models utilize PMP22 immunization to study inflammatory responses .

Genetic Neuropathies

• CMT1A: Caused by PMP22 duplication; PMP22 antibodies help quantify overexpression .

• HNPP: Linked to PMP22 deletions; antibodies validate protein absence .

• Point Mutations: Antibodies like G-6 identify mislocalized PMP22 (e.g., p.C42R, p.Q86X) .

Gene Editing

• AAV-mediated CRISPR/Cas9 systems reduce PMP22 duplication by 20–40% in CMT1A-iPSC models, normalizing myelination .

siRNA Therapy

• Squalenoyl-conjugated siRNA PMP22 nanoparticles restore motor function and electrophysiological parameters in CMT1A mice, with effects lasting 3 weeks .

Research Insights

• Structural Role: PMP22 interacts with myelin protein zero (MPZ) and zonula occludens-1 (ZO-1) to stabilize myelin compaction .

• Non-Neural Expression: PMP22 localizes to epithelial junctions (e.g., liver bile canaliculi), implicating roles beyond myelination .

• Mutation Impact: Truncated PMP22 mutants (e.g., p.I104FfsX7) are retained in the cytosol, disrupting membrane trafficking .

Limitations and Future Directions

• Specificity Challenges: Some antibodies show nonspecific nuclear staining (e.g., EPR26310-118-5) .

• Therapeutic Barriers: siRNA delivery efficiency and CRISPR off-target effects require optimization .